Apoptosis-Inducing TNF Superfamily Ligands for Cancer Therapy

Olivia A Diaz Arguello, Hidde J Haisma*

*Bijbehorende auteur voor dit werk

Onderzoeksoutput: Review articlepeer review

25 Citaten (Scopus)
128 Downloads (Pure)


Cancer is a complex disease with apoptosis evasion as one of its hallmarks; therefore, apoptosis induction in transformed cells seems a promising approach as a cancer treatment. TNF apoptosis-inducing ligands, which are naturally present in the body and possess tumoricidal activity, are attractive candidates. The most studied proteins are TNF-α, FasL, and TNF-related apoptosis-inducing ligand (TRAIL). Over the years, different recombinant TNF family-derived apoptosis-inducing ligands and agonists have been designed. Their stability, specificity, and half-life have been improved because most of the TNF ligands have the disadvantages of having a short half-life and affinity to more than one receptor. Here, we review the outlook on apoptosis-inducing ligands as cancer treatments in diverse preclinical and clinical stages and summarize strategies of overcoming their natural limitations to improve their effectiveness.

Originele taal-2English
Aantal pagina's22
Nummer van het tijdschrift7
StatusPublished - 27-mrt.-2021

Citeer dit